121 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

    Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

    Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.

    • 1 hr 5 min
    April W. Armstrong, MD, MPH - Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis

    April W. Armstrong, MD, MPH - Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis

    Go online to PeerView.com/FXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis. Upon completion of this accredited CE activity, participants should be better able to: Recognize unmet needs in the treatment of moderate to severe psoriasis, Describe the pathophysiology of psoriasis, recognizing current and emerging targets for therapeutic intervention, Summarize efficacy and safety data related to nonbiologic oral therapies and novel cytokine inhibitors for the treatment of moderate to severe psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and individual patient needs, identifying those who would likely derive benefit from novel therapeutic options.

    • 28 min
    Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

    Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

    Go online to PeerView.com/NJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option. Upon completion of this accredited CE activity, participants should be better able to: Explain the role of the JAK-STAT signaling pathway in the pathophysiology of psoriasis, Summarize efficacy and safety data related to current and emerging kinase inhibitors for the treatment of psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and guidelines, recognizing the role of nonbiologic therapies in addressing the burden of disease and comorbidities in individual patients.

    • 37 min
    Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer

    Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer

    Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inhibitors as neoadjuvant and adjuvant systemic therapies in earlier stages of NSCLC, and promising data have started to emerge, including from the first few phase 3 studies. With the continual expansion of immunotherapy into earlier disease settings, multidisciplinary collaboration among thoracic surgeons, medical oncologists, radiation oncologists, and the greater lung cancer care team is paramount. This PeerView Live Seminar and Practicum based on a recent live web broadcast explores the latest advances and clinical trial findings with immunotherapies, analyzes implications for surgical management of patients, and provides case-based, practical guidance for integrating immunotherapies into multimodal management of stage I-III NSCLC in the context of multidisciplinary care. Upon completion of this accredited CE activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.

    • 1 hr 10 min
    Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

    Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

    Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

    • 1 hr 33 min
    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

    Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

    • 27 min

Top Podcasts In Science

Listeners Also Subscribed To